论文部分内容阅读
观察前列腺素Ｅ１（Ｌｉｐｏ ＰＧＥ１）对重症肝炎的疗效和安全性。方法：采用Ｌｉｐｏ ＰＧＥ１注射液治疗５０例重症肝炎，并选择５０例进行综合基础治疗的重症肝炎病人作为对照组，对疗效、存活率、并发症进行观察。结果：治疗组总有效率高于对照组，Ｐ＜０．０１。治疗组中早、中期重症肝炎病人的存活率高于对照组，Ｐ＜０．０５。治疗组中肝肾综合征的发生率明显低于对照组，Ｐ＜０．０５。在治疗过程中，未发生与本药相关的严重不良反应。结论：Ｌｉｐｏ ＰＧＥ１早期使用治疗系症肝炎有明显疗效．能减少肝肾综合征的发生且药物安全性良好。
To observe the efficacy and safety of Lipo PGE1 in severe hepatitis. Methods: Fifty patients with severe hepatitis were treated with Lipo PGE1 injection and 50 patients with severe hepatitis treated by comprehensive basic therapy were selected as the control group. Efficacy, survival rate and complications were observed. Results: The total effective rate in the treatment group was higher than that in the control group (P <0.01). The treatment group in early, mid-term severe hepatitis patients survival rate was higher than the control group, P <0.05. The incidence of hepatorenal syndrome in the treatment group was significantly lower than that in the control group, P <0.05. In the course of treatment, no serious adverse reactions occurred with the drug. Conclusion: Early treatment with Lipo PGE1 has obvious curative effect on hepatitis. Can reduce the incidence of hepatorenal syndrome and drug safety is good.